Atossa Therapeutics Inc (NASDAQ:ATOS) announced it has appointed Jonathan Finn to its board of directors, effective November 8, 2023.
The company noted that Finn has more than 25 years of experience in the financial sector with a focus on mid-stage biotechnology and technology companies, currently serving as executive vice president and chief investment officer at Vantage Consulting Group.
“We are pleased to welcome Jon, who has extensive experience working with clinical-stage biotechnology companies to accelerate growth and commercialize assets, to our board of directors,” Atossa Therapeutics CEO Dr. Steven Quay said in a statement.
“Critical data readouts expected next year will advance our ongoing interactions with regulatory authorities and potential partners, which makes this the perfect time to add someone with Jonathan’s background and network to our board.”
Finn said he was excited to join Atossa’s board and work with the other directors and membership of the leadership team to capitalize on the value of its lead drug candidate (Z)-endoxifen and explore opportunities beyond the current pipeline to deliver additional shareholder value.
“With four ongoing Phase 2 trials and a strong multi-year cash position, I believe the company is well positioned to deliver on its vision of fundamentally changing the breast cancer treatment paradigm,” Finn said. “I look forward to helping them achieve this important goal.”
Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on X, formerly known as Twitter, @emilyjjarvie